Today’s insulin formulations save lives, but achieving tight control over blood-glucose levels remains a daily challenge for those living with type 1 diabetes (T1D). The JDRF Glucose Control Program is committed to making the management of T1D much better and safer through groundbreaking research and clinical trials that aim to develop new ways to help people keep their blood-sugar levels within a healthy range.
Insulin therapy must be calculated carefully, based on food intake, exercise, stress, illness and other (often unpredictable) factors. As a result, people with T1D spend an average of 10 hours a day with blood-sugar levels outside the recommended range, putting them at risk for dangerous high- and low-blood-sugar episodes.
that will automatically respond to blood-sugar levels
—using insulin and other drugs—to dramatically improve daily blood-sugar management
so that no one needs to worry about the risks of low blood-sugar again
“JDRF funded a clinical trial to test whether an SGLT inhibitor, along with insulin, would help keep my blood-sugar levels in a healthy range. After the SGLT inhibitor therapy, I started seeing a straight line in my blood glucose—I wasn’t getting the highs, I wasn’t getting the lows. It was incredible.” Jana C. 56 years old, diagnosed at age 2
“JDRF funded a clinical trial to test whether an SGLT inhibitor, along with insulin, would help keep my blood-sugar levels in a healthy range. After the SGLT inhibitor therapy, I started seeing a straight line in my blood glucose—I wasn’t getting the highs, I wasn’t getting the lows. It was incredible.”
Jana C. 56 years old, diagnosed at age 2
Our research into glucose control technologies is just one potential pathway to finding a cure for T1D. Explore JDRF’s ambitious research portfolio.
Most people with T1D rely solely on insulin to control their glucose levels, but a growing number of researchers are exploring whether non-insulin drugs could be paired with insulin to better manage T1D.
JDRF joins an international consortium of 23 public and private organizations aiming to better understand hypoglycemia, or low blood sugar, and its impact on people with T1D.
JDRF and Gubra announce a partnership to develop glucose-responsive insulin (GRI), a form of insulin designed to work when blood glucose levels rise above healthy levels and to be inactive when blood glucose levels are in or below the standard range.
SGLT inhibition had been approved for type 2 diabetes—and not T1D—but that’s about to change. Dapagliflozin (Farxiga®/Forxiga®) and sotagliflozin (Zynquista™) are submitted for approval for T1D, to be used in addition to insulin therapy to improve glucose control.
In the last decade, more than $45 million has been invested by JDRF in glucose control research. One day, thanks to improved insulin formulations and other drugs, staying within ideal blood-sugar range is no longer a challenge.
Blog
Press Release
